We collect the biopsy tumor FFPE samples derived from 206 therapy-naïve GC patients, and construct a GC cohort that covers three clinical therapy subcohorts, including DOS subcohort (44 patients treated with DOS therapy), XELOX subcohort (70 patients treated with XELOX therapy) and HER2 subcohort (71 patients who received anti-HER2-based therapy). This evidence concerns the gene ERBB2 and gastric cancer.